AGI-5198, also know as IDH-C35, is the a very potent and selective mutant IDH1 inhibitor that was shown to potential anticancer activity. AGI-5198 shows good potency in the U87 R132H cell based assay and ~90% tumor 2-HG inhibition in the corresponding mouse xenograft model following BID dosing. AGI-5198 inhibits IDH1 R132H mutant and R132C mutant in vitro with IC50 ~0.07 μM and ~0.16 μM, respectively.
Dehydrogenase Inhibitors Related Products:
Mycophenolate mofetil; SW033291; Vidofludimus; AGI-6780; Devimistat (CPI-613); Mycophenolic acid; Trilostane; Tenovin-1; Teriflunomide; Gimeracil; AG-636; AG-120 (racemic); Ivosidenib; Brequinar